Rotavirus Vaccine, Human, Lyophilised
Not recommended VaccinesNot applicable line
Prevention of rotavirus gastroenteritis in infants, proposed for vaccination of all infants at 2 and 4 months of age.
1
Submissions
2006–06
On the record
$15k–45k
ICER range
1 sourced ICER · 2006
ICER stated
Cost basis
Cost-effectiveness
The incremental cost per extra QALY gained was between $15,000 - $45,000. PSD · 2006
Decision context
PopulationAll healthy infants at 2 and 4 months of age to prevent rotavirus gastroenteritis
Why it was knocked back
- uncertain cost-effectiveness at the price requested, concerns about treatment of QALY gains, substantial framing bias in disutility elicitation for standard gamble, concerns with discrete choice experiment framing methodology, uncertainty about indirect benefits valuation, omission of administration costs for oral vaccine
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2006 | Not recommended | placebo (standard medical management) | $15k–45k | RCT · Severe RVGE efficacy |